Recent Xarelto Lawsuit Filed By New York PlaintiffFederal internal bleeding lawsuits are filed against the manufacturers of Xarelto, alleging the drug can cause serious, uncontrollable internal bleeding. A Texas woman has recently filed a lawsuit in New York state against the manufacturers of the anticoagulant drug Xarelto, Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson.
The lawsuit is filed in federal court for the Eastern District of New York and is listed under federal court docket number 1:14-CV-04524. It is alleging that the manufacturer's failure to adequately warn patients and doctors about the dangers of the drug and failure to perform sufficient safety testing on the blood thinner led to her serious injuries. To download and read the full complaint, click here.
In this case, the plaintiff began to take Xarelto after her doctor prescribed it to her to prevent blood clots that could develop from her heart condition, atrial fibrillation. She took the blood thinner regularly for five months until she suffered from a very serious life threatening internal bleeding event. The internal bleed left her with a serious injury. The complaint filed did not go into specifics about the exact nature of the injuries she suffered, but it did state that the injuries suffered as a result of the uncontrollable, internal bleeding are permanent and require long term, future care.
Increasing Number of Xarelto Lawsuits Filed
The lawsuit filed in New York is just one of the many that have recently been filed against the manufacturers of Xarelto. These lawsuits filed all make similar allegations that the Texas woman makes, that Xarelto can cause severe, uncontrollable internal bleeding and that the manufacturers failed to adequately warn patients and doctors about the true dangers of the drug.
Xarelto is more dangerous than other blood thinners available on the market because there is currently no available antidote for the anticoagulant effects of the drug. Xarelto is a part of a new class of blood thinners known as Xa inhibitors. Xa inhibitors prevent clots by blocking the chemical in the blood that is responsible for making blood clot, thrombin. By blocking thrombin, Xarelto completely takes away the blood's ability to clot. In the case of more traditional blood thinners, such as Warfarin, if a patient suffers from an internal bleeding event while taking the drug, a doctor can administer vitamin K to reverse the effects of Warfarin and make the blood clot again. In contrast, if a patient is taking Xarelto, the drug is active in their system, and they suffer from an internal bleeding emergency, there is no medical way, short of extreme life-saving measures, to make the blood clot and stop the bleed.
As of December 2014, the federally filed lawsuits against the manufacturers of Xarelto have been consolidated into a federal multidistrict litigation in the United States District Court for the Eastern District of Louisiana.
"If you or a loved one have suffered from an injury after taking Xarelto, contact us immediately." Xarelto attorney Marc Goldich said, "You may be entitled to significant compensation for your pain and suffering."
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.